The impact of p16ink4a positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study.
Arch Gynecol Obstet
; 301(3): 753-759, 2020 03.
Article
en En
| MEDLINE
| ID: mdl-31970493
ABSTRACT
PURPOSE:
To evaluate HPV and p16ink4a status as prognostic factors in patients with invasive vulvar cancer.METHODS:
Retrospective analysis of disease-free (DFS) and disease-specific survival (DSS) of patients with invasive vulvar cancer at a single tertiary care center. Histology, HPV and p16ink4a status were evaluated in the context of a global multicenter trial. Logistic regression models were performed to identify the impact of p16ink4a positivity.RESULTS:
135 patients were included in the analysis. 32 (23.7%) showed a p16ink4a expression of over 25%. Disease-free and disease-specific survival was longer in p16ink4a positive patients (23 vs. 10 months, p = 0.004, respectively, 29 vs. 21 months, p = 0.016). In multivariate analysis, p16ink4a positivity was an independent parameter for DFS (p = 0.025, HR 2.120 (1.100-4.085)), but not for DSS (p = 0.926, HR 1.029 (0.558-1.901), in contrast to age and tumor stage.CONCLUSIONS:
Age and tumor stage negatively affect survival. However, disease-free survival is significantly longer in patients with p16ink4a positive invasive vulvar cancer.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Vulva
/
Biomarcadores de Tumor
/
Inhibidor p16 de la Quinasa Dependiente de Ciclina
Tipo de estudio:
Observational_studies
/
Prognostic_studies
Límite:
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Año:
2020
Tipo del documento:
Article